Filters
![](https://cdn.prod.website-files.com/64c2a9ec9c767dc6142b968b/66a02d3fc7153a2f351e51c2_Sergey%20Brin.jpeg)
Psychedelics
Google's Co-Founder Is Backing A Psychedelic Startup
Google (NASDAQ:GOOG) co-founder Sergey Brin has backed psychedelic medicine startup Soneira with a $15 million investment to advance their ibogaine research.
July 22, 2024
Psychedelics
Biotech
Venture Capital
![](https://cdn.prod.website-files.com/64c2a9ec9c767dc6142b968b/665f0992002b1f8d7712af0c_MDMA%20and%20Psilocybin.jpeg)
Psychedelics
Optimi Health Is Now Legally Producing MDMA and Psilocybin Capsules
Optimi Health (CSE:OPTI) has been awarded a Drug Establishment License from Health Canada to manufacture and sell psilocybin and MDMA capsules.
June 3, 2024
Biotech
Psychedelics
Public Companies
Regulatory
![](https://cdn.prod.website-files.com/64c2a9ec9c767dc6142b968b/66439578a8337958af064bc6_Psychedelic%20Pills.jpeg)
Psychedelics
Big Pharma Is Making Another Move Into Psychedelic Drug Development
Pharmaceutical giant AbbVie (NYSE: ABBV) has announced a new partnership with psychedelic drug developer Gilgamesh Pharmaceuticals to develop psychedelic drugs.
May 13, 2024
Biotech
Public Companies
![](https://cdn.prod.website-files.com/64c2a9ec9c767dc6142b968b/663e3c6a55230ee34f8b3d2b_Pill%20Capsule.png)
Psychedelics
Compass Pathways Is On The Verge Of Another Psychedelic Breakthrough
Psychedelic drug developer Compass Pathways (NASDAQ:CMPS) has announced early clinical validation for their novel synthetic psilocybin compound.
May 9, 2024
Biotech
Psychedelics
Public Companies
Regulatory
![](https://cdn.prod.website-files.com/64c2a9ec9c767dc6142b968b/65fd6e7c602f94ff014a5c0d_Psychedelic%20Pills.jpeg)
Psychedelics
Psychedelics Are On The Verge Of Creating A Biotech Revolution
Psychedelic drug developers have been on a rapid rise, with multiple new Breakthrough Therapy designations from the FDA and significant venture capital raises.
March 21, 2024
Biotech
Psychedelics
Public Companies
Regulatory
Venture Capital
![](https://cdn.prod.website-files.com/64c2a9ec9c767dc6142b968b/65f82cb623b7bc75d7795d75_Oxycontin.jpeg)
Psychedelics
Gilgamesh Lands Government Grant To Solve Opioid Addiction
Gilgamesh has received a $14 million grant from the National Institute on Drug Abuse to advance the clinical development of their novel cardiac-safe ibogaine.
March 16, 2024
Biotech
Regulatory
Startups
![](https://cdn.prod.website-files.com/64c2a9ec9c767dc6142b968b/65f3606f0bbd7fcb26675806_Psilocybin%202.jpeg)
Psychedelics
Psychedelic Depression Drug Lands Breakthrough Therapy Designation From The FDA
Cybin (NYSE: CYBN) has been granted a Breakthrough Therapy designation from the FDA for their novel psychedelic molecule CYB003 for Major Depressive Disorder.
March 14, 2024
Psychedelics
Public Companies
Biotech
![](https://cdn.prod.website-files.com/64c2a9ec9c767dc6142b968b/65eb6e55fb15ff3e5e3becc7_LSD%20Pill%20Capsule2.jpeg)
Psychedelics
MindMed Receives Breakthrough Therapy Designation From FDA For LSD
Psychedelic biotechnology company MindMed (NASDAQ: MNMD) has received a Breakthrough Therapy designation from the United States FDA for their novel drug MM120.
March 7, 2024
Biotech
Psychedelics
Public Companies